Gilead Sciences halts drug studies over side effects, death

Gilead Sciences halts drug studies over side effects, death


Biologic drugmaker Gilead Sciences Inc. has halted several patient studies of its cancer drug, Zydelig, because of increased risk of death and serious side effects. The company told The Associated Press the "adverse events" were spotted during an ongoing review of late-stage testing in patients with chronic lymphocytic leukemia, a blood cancer, and patients with relapsed non-Hodgkin's lymphoma, a cancer of the infection-fighting lymphatic system.



from Biotech News